HK1219871A1 - Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell (epo) - Google Patents

Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell (epo)

Info

Publication number
HK1219871A1
HK1219871A1 HK16107786.5A HK16107786A HK1219871A1 HK 1219871 A1 HK1219871 A1 HK 1219871A1 HK 16107786 A HK16107786 A HK 16107786A HK 1219871 A1 HK1219871 A1 HK 1219871A1
Authority
HK
Hong Kong
Prior art keywords
epo
mediated
composition
inducing
mitochondrial biogenesis
Prior art date
Application number
HK16107786.5A
Other languages
Chinese (zh)
Inventor
吳榮燦
Original Assignee
Wu Sophia Shu Fen
Wu Rong-Tsun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wu Sophia Shu Fen, Wu Rong-Tsun filed Critical Wu Sophia Shu Fen
Publication of HK1219871A1 publication Critical patent/HK1219871A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16107786.5A 2013-03-28 2016-07-05 Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell (epo) HK1219871A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/034381 WO2014158165A1 (en) 2013-03-28 2013-03-28 Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell

Publications (1)

Publication Number Publication Date
HK1219871A1 true HK1219871A1 (en) 2017-04-21

Family

ID=51624947

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107786.5A HK1219871A1 (en) 2013-03-28 2016-07-05 Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell (epo)

Country Status (8)

Country Link
EP (1) EP2978417A4 (en)
JP (1) JP2016516745A (en)
KR (1) KR20150135430A (en)
CN (1) CN105188688A (en)
AU (1) AU2013384234A1 (en)
CA (1) CA2907965C (en)
HK (1) HK1219871A1 (en)
WO (1) WO2014158165A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102606948B1 (en) * 2015-06-16 2023-11-27 롱-쭌 우 How to Treat or Prevent Dry Eye
WO2017012289A1 (en) 2015-07-23 2017-01-26 Rong-Tsun Wu New compounds as positive allosteric modulators for erythropoietin and erythropoietin receptor to treat erythropoietin deficiency diseases
CN106822160A (en) * 2017-02-16 2017-06-13 中国人民解放军第四军医大学 Application of the Stibene-glucoside in the medicine and health products for preparing obesity-related hypertension
CN107349213A (en) * 2017-07-10 2017-11-17 苏州神瑞生物科技有限公司 Applied based on the synthesising preparation of Stibene-glucoside in treatment nerve degenerative diseases medicine is prepared
CN109999047A (en) * 2019-04-19 2019-07-12 浙江大学 Two-step method screens mitochondrial disease drug
CN113599357B (en) * 2021-07-30 2023-03-24 中国医学科学院生物医学工程研究所 Application of ROS (reactive oxygen species) -responsive nanoparticles coated with hematopoietic growth factors in preparation of drugs for treating hematopoietic injuries

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044370A1 (en) * 1999-01-29 2000-08-03 Sunstar Inc. Drugs, foods and oral compositions containing stilbene-type compounds
US20050042314A1 (en) * 2003-08-22 2005-02-24 National Yang-Ming University Extracts of Polygonum multiflorum Thunb., and preparation process and uses of the same
US7824714B2 (en) * 2008-06-13 2010-11-02 Development Center For Biotechnology Chinese herb extract for treating dementia and preparation method thereof
US20100160243A1 (en) * 2008-12-24 2010-06-24 National Yang-Ming University Compounds and methods for enhancing erythropoiesis

Also Published As

Publication number Publication date
WO2014158165A1 (en) 2014-10-02
CA2907965C (en) 2021-12-07
AU2013384234A1 (en) 2015-10-15
JP2016516745A (en) 2016-06-09
EP2978417A4 (en) 2017-03-01
CN105188688A (en) 2015-12-23
KR20150135430A (en) 2015-12-02
CA2907965A1 (en) 2014-10-02
EP2978417A1 (en) 2016-02-03

Similar Documents

Publication Publication Date Title
EP2923791A4 (en) Machining device and machining method
HK1219871A1 (en) Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell (epo)
EP2962801A4 (en) Machining device and machining method
GB201305822D0 (en) Improvements in and relating to apparatus and methods
GB201407698D0 (en) Improvements in and relating to ophthalmo-scopes
EP3008541A4 (en) Methods and apparatus to provide power to devices
EP3002687A4 (en) Method and device for recreating index online
GB201305414D0 (en) Method and composition
PT3084558T (en) Power saving techniques in computing devices
EP2772854A4 (en) Regulation method and regulation device for i/o channels in virtualization platform
PT2945482T (en) Compositions and methods for stabilizing 1-methylcyclopropene in solutions
GB201402102D0 (en) Improvements in and relating to electrical contactors
HK1222561A1 (en) Compositions and methods for use in oncology
GB201603139D0 (en) Improvements in and relating to lenses
GB2517145B (en) Improvements in and relating to packaging apparatus
GB201409388D0 (en) Improvements in and relating to boxes
EP3017540A4 (en) Apparatus and method in apparatus
EP2712134A4 (en) Cell concatenation processing method and device
GB2536338B (en) Improvements in and relating to electrical controllers
GB2551414B (en) Improvements in and relating to packaging apparatus
GB2516964B (en) Improvements in and relating to packaging apparatus
IL243091B (en) Compositions and methods for use in oncology
GB201303203D0 (en) Improvements in and relating to storage apparatus
GB201318468D0 (en) Improvements in and relating to processing methods and processing apparatus
EP3009926A4 (en) Direct table storage method and device